CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

CAT

700.75

+3.06%↑

GE

292.59

+2.42%↑

RTX

194.56

-1.74%↓

GEV.US

881.02

+3.47%↑

BA

198.57

+1.76%↑

Search

Verisk Analytics Inc

Uždarymo kaina

SektoriusPramonės sektorius

200.17 -0.73

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

197.74

Max

202.43

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-28M

197M

Pardavimai

11M

779M

P/E

Sektoriaus vid.

31.068

61.065

Dividendų pajamingumas

0.89

Pelno marža

25.321

Darbuotojai

8,000

EBITDA

10M

418M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+16.11% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.89%

2.23%

Kitas uždarbis

2026-05-06

Kitas dividendų mokėjimo data

2026-03-31

Kita Ex Dividend data

2026-06-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.2B

29B

Ankstesnė atidarymo kaina

200.9

Ankstesnė uždarymo kaina

200.17

Naujienos nuotaikos

By Acuity

53%

47%

322 / 406 reitingas Industrials

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Verisk Analytics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-23 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026-03-23 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026-03-23 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026-03-23 23:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-23 23:59; UTC

Rinkos pokalbiai

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026-03-23 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026-03-23 23:37; UTC

Rinkos pokalbiai

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026-03-23 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026-03-23 22:23; UTC

Rinkos pokalbiai

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026-03-23 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026-03-23 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026-03-23 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026-03-23 22:08; UTC

Rinkos pokalbiai

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026-03-23 21:10; UTC

Svarbiausios naujienos

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026-03-23 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai
Uždarbis
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Verisk Analytics Inc Prognozė

Kainos tikslas

By TipRanks

16.11% į viršų

12 mėnesių prognozė

Vidutinis 234.25 USD  16.11%

Aukščiausias 275 USD

Žemiausias 216 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Verisk Analytics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

8

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

294.51 / 309.9Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

322 / 406 reitingas Pramonės sektorius

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Verisk Analytics Inc

Verisk Analytics, Inc. provides data analytics and technology solutions to the insurance markets in the United States and internationally. It offers policy language, prospective loss costs, policy writing and rating rules, and various underwriting solutions for risk selection and segmentation, pricing, and workflow optimization; property- and auto- specific rating and underwriting information solutions that allows clients to understand, quantify, underwrite, mitigate, and avoid potential loss for risks; catastrophe modeling solutions, which enables companies to identify, quantify, and plan for the financial consequences of catastrophes for use by insurers, reinsurers, intermediaries, financial institutions, and governments. The company also provides life insurance solutions for transforming current workflows in life insurance underwriting, claim insights, policy administration, unclaimed property/equity, compliance and fraud detection, and actuarial and portfolio modeling; Marketing Solutions, such as compliant, real-time decisioning, profitability, and risk assessment for inbound consumer interactions; and international underwriting and claims solutions. In addition, it offers claims insurance solutions, which provides analytics in fraud detection, compliance reporting, subrogation liability assessment, litigation, and repair cost estimation and valuation solutions; and casualty solutions, such as compliance, casualty claims decision support, and workflow automation solutions. Further, the company supplies software to the specialty insurance market. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.
help-icon Live chat